Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates Nov 12, 2024
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Nov 12, 2024
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma Nov 07, 2024
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea Nov 04, 2024
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference Oct 25, 2024
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference Oct 03, 2024
